Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival

Cell Death and Disease

Volumn 8, Issue 3, 2017, Pages

  Thole, Theresa M ^a,b,c   Lodrini, Marco ^a,c   Fabian, Johannes ^c   Wuenschel, Jasmin ^a,c   Pfeil, Sebastian ^a   Hielscher, Thomas ^c   Kopp Schneider, Annette ^c   Heinicke, Ulrike ^d   Fulda, Simone ^c,d   Witt, Olaf ^b,c   Eggert, Angelika ^a   Fischer, Matthias ^e   Deubzer, Hedwig E ^a,b,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE 3; CENTROMERE PROTEIN A; CENTROMERE PROTEIN E; DLG ASSOCIATED PROTEIN 5; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 8; HISTONE H3; KINESIN; KINESIN FAMILY MEMBER 14; KINESIN FAMILY MEMBER 23; MITOTIC ARREST DEFICIENT LIKE 1 PROTEIN; RAC GTPASE ACTIVATING PROTEIN 1; SMALL INTERFERING RNA; UBIQUITIN LIKE WITH PHD AND RING FINGER DOMAIN 1; UNCLASSIFIED DRUG; HDAC11 PROTEIN, HUMAN; HISTONE DEACETYLASE;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL DEATH; CELL DIVISION; CELL SURVIVAL; CELL VIABILITY; CLINICAL ASSESSMENT; CONTROLLED STUDY; EVENT FREE SURVIVAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MITOSIS; MITOSIS SPINDLE; NEUROBLASTOMA CELL LINE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN DEPLETION; TREATMENT OUTCOME; CELL CYCLE; DISEASE FREE SURVIVAL; GENE; GENETICS; METABOLISM; NEUROBLASTOMA; TUMOR CELL LINE; TUMOR RECURRENCE;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE-FREE SURVIVAL; GENE EXPRESSION; GENES, CDC; HISTONE DEACETYLASES; HUMANS; MITOSIS; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA;

EID: 85014507021     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2017.49     Document Type: Article

References (84)

1. Maris JM. Recent advances in neuroblastoma. New Engl J Med 2010; 362: 2202-2211.
2. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983; 305: 245-248.
3. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121-1124.
4. Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 2015; 526: 700-704.
5. Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet 2015; 47: 1411-1414.
6. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012; 483: 589-593.
7. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-935.
8. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455: 971-974.
9. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455: 967-970.
10. George RE, Sanda T, Hanna M, Frohling S, Luther W 2nd, Zhang J, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455: 975-978.
11. Witt O, Deubzer HE, Lodrini M, Milde T, Oehme I. Targeting histone deacetylases in neuroblastoma. Curr Pharm Des 2009; 15: 436-447.
12. Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, et al. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 2014; 26: 414-427.
13. Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, et al. Targeting MYCN-driven transcription by BET-bromodomain inhibition. Clin Cancer Res 2016; 22: 2470-2481.
14. Lakoma A, Barbieri E, Agarwal S, Jackson J, Chen Z, Kim Y, et al. The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma. Cell Death Discov 2015; 1: 15026.
15. Woodfield SE, Zhang L, Scorsone KA, Liu Y, Zage PE. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer 2016; 16: 172.
16. Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res 2013; 19: 6173-6182.
17. Juo YY, Gong XJ, Mishra A, Cui X, Baylin SB, Azad NS, et al. Epigenetic therapy for solid tumors: from bench science to clinical trials. Epigenomics 2015; 7: 215-235.
18. Liu T, Tee AE, Porro A, Smith SA, Dwarte T, Liu PY, et al. Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proc Natl Acad Sci USA 2007; 104: 18682-18687.
19. Lodrini M, Oehme I, Schroeder C, Milde T, Schier MC, Kopp-Schneider A, et al. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res 2013; 41: 6018-6033.
20. Fabian J, Lodrini M, Oehme I, Schier MC, Thole TM, Hielscher T, et al. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. Cancer Res 2014; 74: 2604-2616.
21. Sun Y, Liu PY, Scarlett CJ, Malyukova A, Liu B, Marshall GM, et al. Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc. Oncogene 2014; 33: 2987-2994.
22. Rettig I, Koeneke E, Trippel F, Mueller WC, Burhenne J, Kopp-Schneider A, et al. Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. Cell Death Dis 2015; 6: e1657.
23. Oehme I, Linke JP, Bock BC, Milde T, Lodrini M, Hartenstein B, et al. Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc Natl Acad Sci USA 2013; 110: E2592-E2601.
24. Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 2002; 277: 25748-25755.
25. Glozak MA, Seto E. Acetylation/deacetylation modulates the stability of DNA replication licensing factor Cdt1. J Biol Chem 2009; 284: 11446-11453.
26. Deubzer HE, Schier MC, Oehme I, Lodrini M, Haendler B, Sommer A, et al. HDAC11 is a novel drug target in carcinomas. Int J Cancer 2013; 132: 2200-2208.
27. Biedler JL, Spengler BA. A novel chromosome abnormality in human neuroblastoma and antifolate-resistant Chinese hamster cell lives in culture. J Natl Cancer Inst 1976; 57: 683-695.
28. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 2001; 61: 8-13.
29. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, et al. Metaanalysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010; 16: 4353-4362.
30. Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010; 28: 3506-3515.
31. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27: 289-297.
32. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012; 90: 85-94.
33. Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 2014; 159: 1126-1139.
34. Mao L, Ding J, Perdue A, Yang L, Zha Y, Ren M, et al. Cyclin E1 is a common target of BMI1 and MYCN and a prognostic marker for neuroblastoma progression. Oncogene 2012; 31: 3785-3795.
35. Bostick M, Kim JK, Esteve PO, Clark A, Pradhan S, Jacobsen SE. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 2007; 317: 1760-1764.
36. Falk SJ, Lee J, Sekulic N, Sennett MA, Lee TH, Black BE. CENP-C directs a structural transition of CENP-A nucleosomes mainly through sliding of DNA gyres. Nat Struct Mol Biol 2016; 23: 204-208.
37. Guse A, Carroll CW, Moree B, Fuller CJ, Straight AF. In vitro centromere and kinetochore assembly on defined chromatin templates. Nature 2011; 477: 354-358.
38. Zlotorynski E. Chromosome biology: controlling CENPA mislocalization. Nat Rev Mol Cell Biol 2014; 15: 368.
39. Hori T, Okada M, Maenaka K, Fukagawa T. CENP-O class proteins form a stable complex and are required for proper kinetochore function. Mol Biol Cell 2008; 19: 843-854.
40. Li T, Chen L, Cheng J, Dai J, Huang Y, Zhang J, et al. SUMOylated NKAP is essential for chromosome alignment by anchoring CENP-E to kinetochores. Nat Commun 2016; 7: 12969.
41. Hou S, Li N, Zhang Q, Li H, Wei X, Hao T, et al. XAB2 functions in mitotic cell cycle progression via transcriptional regulation of CENPE. Cell Death Dis 2016; 7: e2409.
42. Balamuth NJ, Wood A, Wang Q, Jagannathan J, Mayes P, Zhang Z, et al. Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. Cancer Res 2010; 70: 2749-2758.
43. Koffa MD, Casanova CM, Santarella R, Kocher T, Wilm M, Mattaj IW. HURP is part of a Randependent complex involved in spindle formation. Curr Biol 2006; 16: 743-754.
44. Rice S. Structure of kif14: an engaging molecular motor. J Mol Biol 2014; 426: 2993-2996.
45. Osako Y, Seki N, Kita Y, Yonemori K, Koshizuka K, Kurozumi A, et al. Regulation of MMP13 by antitumor microRNA-375 markedly inhibits cancer cell migration and invasion in esophageal squamous cell carcinoma. Int J Oncol 2016; 49: 2255-2264.
46. Wang W, Shi Y, Li J, Cui W, Yang B. Up-regulation of KIF14 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in cervical cancer. Biosci Rep 2016; 36: e00315.
47. Theriault BL, Cybulska P, Shaw PA, Gallie BL, Bernardini MQ. The role of KIF14 in patientderived primary cultures of high-grade serous ovarian cancer cells. J Ovarian Res 2014; 7: 123.
48. Wang Q, Wang L, Li D, Deng J, Zhao Z, He S, et al. Kinesin family member 14 is a candidate prognostic marker for outcome of glioma patients. Cancer Epidemiol 2013; 37: 79-84.
49. Madhavan J, Mitra M, Mallikarjuna K, Pranav O, Srinivasan R, Nagpal A, et al. KIF14 and E2F3 mRNA expression in human retinoblastoma and its phenotype association. Mol Vis 2009; 15: 235-240.
50. O'Hare M, Shadmand M, Sulaiman RS, Sishtla K, Sakisaka T, Corson TW. Kif14 overexpression accelerates murine retinoblastoma development. Int J Cancer 2016; 139: 1752-1758.
51. Huang W, Wang J, Zhang D, Chen W, Hou L, Wu X, et al. Inhibition of KIF14 suppresses tumor cell growth and promotes apoptosis in human glioblastoma. Cell Physiol Biochem 2015; 37: 1659-1670.
52. Yang T, Zhang XB, Zheng ZM. Suppression of KIF14 expression inhibits hepatocellular carcinoma progression and predicts favorable outcome. Cancer Sci 2013; 104: 552-557.
53. Hung PF, Hong TM, Hsu YC, Chen HY, Chang YL, Wu CT, et al. The motor protein KIF14 inhibits tumor growth and cancer metastasis in lung adenocarcinoma. PLoS ONE 2013; 8: e61664.
54. Markowski J, Tyszkiewicz T, Jarzab M, Oczko-Wojciechowska M, Gierek T, Witkowska M, et al. Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma. Eur Arch Otorhinolaryngol 2009; 266: 1501-1507.
55. Lagarde P, Przybyl J, Brulard C, Perot G, Pierron G, Delattre O, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol 2013; 31: 608-615.
56. Szponar A, Zubakov D, Pawlak J, Jauch A, Kovacs G. Three genetic developmental stages of papillary renal cell tumors: duplication of chromosome 1q marks fatal progression. Int J Cancer 2009; 124: 2071-2076.
57. Corson TW, Gallie BL. KIF14 mRNA expression is a predictor of grade and outcome in breast cancer. Int J Cancer 2006; 119: 1088-1094.
58. Brynychova V, Ehrlichova M, Hlavac V, Nemcova-Furstova V, Pecha V, Leva J, et al. Genetic and functional analyses do not explain the association of high PRC1 expression with poor survival of breast carcinoma patients. Biomed Pharmacother 2016; 83: 857-864.
59. Singel SM, Cornelius C, Zaganjor E, Batten K, Sarode VR, Buckley DL, et al. KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. Neoplasia 2014; 16: 247-256, e242.
60. Ahmed SM, Theriault BL, Uppalapati M, Chiu CW, Gallie BL, Sidhu SS, et al. KIF14 negatively regulates Rap1a-Radil signaling during breast cancer progression. J Cell Biol 2012; 199: 951-967.
61. Abiatari I, DeOliveira T, Kerkadze V, Schwager C, Esposito I, Giese NA, et al. Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Mol Cancer Ther 2009; 8: 1494-1504.
62. Corson TW, Huang A, Tsao MS, Gallie BL. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 2005; 24: 4741-4753.
63. Li Y, Benezra R. Identification of a human mitotic checkpoint gene: hsMAD2. Science 1996; 274: 246-248.
64. Valentijn LJ, Koster J, Haneveld F, Aissa RA, van Sluis P, Broekmans ME, et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci USA 2012; 109: 19190-19195.
65. Fischer M, Grundke I, Sohr S, Quaas M, Hoffmann S, Knorck A, et al. p53 and cell cycle dependent transcription of kinesin family member 23 (KIF23) is controlled via a CHR promoter element bound by DREAM and MMB complexes. PLoS ONE 2013; 8: e63187.
66. Nishimura K, Oki T, Kitaura J, Kuninaka S, Saya H, Sakaue-Sawano A, et al. APC(CDH1) targets MgcRacGAP for destruction in the late M phase. PLoS ONE 2013; 8: e63001.
67. Mishima M, Kaitna S, Glotzer M. Central spindle assembly and cytokinesis require a kinesinlike protein/RhoGAP complex with microtubule bundling activity. Dev Cell 2002; 2: 41-54.
68. Canman JC, Lewellyn L, Laband K, Smerdon SJ, Desai A, Bowerman B, et al. Inhibition of Rac by the GAP activity of centralspindlin is essential for cytokinesis. Science 2008; 322: 1543-1546.
69. Pliarchopoulou K, Kalogeras KT, Kronenwett R, Wirtz RM, Eleftheraki AG, Batistatou A, et al. Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Cancer Chemother Pharmacol 2013; 71: 245-255.
70. Wang SM, Ooi LL, Hui KM. Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. Clin Cancer Res 2011; 17: 6040-6051.
71. Ke HL, Ke RH, Li ST, Li B, Lu HT, Wang XQ. Expression of RACGAP1 in high grade meningiomas: a potential role in cancer progression. J Neurooncol 2013; 113: 327-332.
72. Liang Y, Liu M, Wang P, Ding X, Cao Y. Analysis of 20 genes at chromosome band 12q13: RACGAP1 and MCRS1 overexpression in nonsmall-cell lung cancer. Genes Chromosomes Cancer 2013; 52: 305-315.
73. Fabian J, Opitz D, Althoff K, Lodrini M, Hero B, Volland R, et al. MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma. Oncotarget 2016; 7: 66344-66359.
74. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 2009; 15: 91-99.
75. Schmitt M, Pawlita M. High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res 2009; 37: e119.
76. Castro F, Dirks WG, Fahnrich S, Hotz-Wagenblatt A, Pawlita M, Schmitt M. High-throughput SNP-based authentication of human cell lines. Int J Cancer 2013; 132: 308-314.
77. Heinicke U, Kupka J, Fichter I, Fulda S. Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma. Oncogene 2016; 35: 3729-3741.
78. Eberwine J, Yeh H, Miyashiro K, Cao Y, Nair S, Finnell R, et al. Analysis of gene expression in single live neurons. Proc Natl Acad Sci USA 1992; 89: 3010-3014.
79. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30: 207-210.
80. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004: 3. Article3.
81. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Methodol 1995; 57: 289-300.
82. Wang X, Terfve C, Rose JC, Markowetz F. HTSanalyzeR: an R/Bioconductor package for integrated network analysis of high-throughput screens. Bioinformatics 2011; 27: 879-880.
83. RFfSC RDCT. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria, 2013. Available at: http://wwwR-projectorg/2013.
84. Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics 1992; 48: 85.